CC BY 4.0 · Journal of Child Science 2023; 13(01): e35-e39
DOI: 10.1055/s-0043-1768243
Original Article

Factors Associated with Failure of Stepping-Down Treatment in Pediatric Asthma

Wijittra Krobtrakulchai
1   Department of Pediatrics, Maharat Nakorn Ratchasima Hospital, Nakorn Ratchasima Province, Thailand
› Author Affiliations


Background The international and Thai asthma guidelines recommend stepping-down controller treatment in patients whose asthma symptoms have been controlled and maintained for 3 months or longer. After stepping-down treatment, some patients experienced exacerbations and required emergency care. There is limited understanding of stepping-down treatment for asthmatic children. The goal of this study was to determine the failure rate and associated factors after stepping-down treatment in pediatric asthma.

Methods A retrospective study of electronic medical records of asthmatic patients aged between 3 and 15 years with controlled symptoms and indications for stepping-down treatment was conducted at Maharat Nakhon Ratchasima Hospital, a tertiary care center in Northeast Thailand, between January 2015 and December 2019.

Results Of the 110 asthmatic patients with well-controlled asthma who received stepping-down treatment, 90 patients were followed over 12 months. Failure of treatment within 12 months of follow-up was 37.8% (34 of 90). Patients who failed to stepping-down treatment had asthma onset at a younger age (p = 0.026) and less than 9 months duration of asthma stability before stepping-down (p = 0.049). In multivariate analysis, the factor associated with failed stepping-down treatment was the length of asthma stability of fewer than 9 months with an odds ratio of 4.8 (95% confidence interval: 1.02–22.47).

Conclusion Stepping-down treatment in well-controlled pediatric asthma resulted in a high failure rate. The author suggests initiating stepping-down treatment in patients whose duration of asthma stability is greater than 9 months may improve the rate of success.

Publication History

Received: 26 September 2022

Accepted: 08 March 2023

Article published online:
12 April 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • References

  • 1 Global Initiative for Asthma. Global strategy for asthma management and prevention 2022 [Internet]. [place unknown]: Global Initiative for Asthma; c2022 [cited 2022 Dec 3]. Accessed March 23, 2023 at:
  • 2 Trakultivakorn M, Sangsupawanich P, Vichyanond P. Time trends of the prevalence of asthma, rhinitis and eczema in Thai children-ISAAC (International Study of Asthma and Allergies in Childhood) Phase Three. J Asthma 2007; 44 (08) 609-611
  • 3 Rank MA, Liesinger JT, Branda ME. et al. Comparative safety and costs of stepping down asthma medications in patients with controlled asthma. J Allergy Clin Immunol 2016; 137 (05) 1373-1379 .e3
  • 4 Loke YK, Blanco P, Thavarajah M, Wilson AM. Impact of Inhaled corticosteroids on growth in children with asthma: systematic review and meta-analysis. PLoS One 2015; 10 (07) e0133428
  • 5 Sannarangappa V, Jalleh R. Inhaled corticosteroids and secondary adrenal insufficiency. Open Respir Med J 2014; 8: 93-100
  • 6 Fuchs O, Bahmer T, Rabe KF, von Mutius E. Asthma transition from childhood into adulthood. Lancet Respir Med 2017; 5 (03) 224-234
  • 7 Wang AL, Datta S, Weiss ST, Tantisira KG. Remission of persistent childhood asthma: Early predictors of adult outcomes. J Allergy Clin Immunol 2019; 143 (05) 1752-1759 .e6
  • 8 Bernstein JA, Mansfield L. Step-up and step-down treatments for optimal asthma control in children and adolescents. J Asthma 2019; 56 (07) 758-770
  • 9 Rogers L, Reibman J. Stepping down asthma treatment: how and when. Curr Opin Pulm Med 2012; 18 (01) 70-75
  • 10 Rank MA, Hagan JB, Park MA. et al. The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2013; 131 (03) 724-729
  • 11 Yamasaki A, Tomita K, Kato K. et al. Development and validation of a predictive model of failed stepping-down of inhaled corticosteroids in adult asthmatics. Patient Prefer Adherence 2016; 10 (10) 339-344
  • 12 Martínez-Moragón E, Delgado J, Mogrovejo S. et al; en nombre del grupo de investigación STEP, ; Los autores quieren agradecer su colaboración a los siguientes investigadores participantes ordenados alfabéticamente. Factors that determine the loss of control when reducing therapy by steps in the treatment of moderate-severe asthma in standard clinical practice: a multicentre Spanish study. Rev Clin Esp (Barc) 2020; 220 (02) 86-93
  • 13 Rank MA, Branda ME, McWilliams DB. et al. Outcomes of stepping down asthma medications in a guideline-based pediatric asthma management program. Ann Allergy Asthma Immunol 2013; 110 (05) 354-358 .e2
  • 14 Rank MA, Johnson R, Branda M. et al. Long term outcomes after stepping down asthma controller medications: a claims-based, time-to-events analysis. Chest 2015; 148 (03) 630-639
  • 15 DiMango E, Rogers L, Reibman J. et al. Risk factors for asthma exacerbation and treatment failure in adults and adolescents with well-controlled asthma during continuation and step-down therapy. Ann Am Thorac Soc 2018; 15 (08) 955-961
  • 16 Pérez de Llano L, García-Rivero JL, Urrutia I. et al. A simple score for future risk prediction in patients with controlled asthma who undergo a guidelines-based step-down strategy. J Allergy Clin Immunol Pract 2019; 7 (04) 1214-1221 .e3
  • 17 Koskela HO, Purokivi MK, Kokkarinen J. Stepping down from combination asthma therapy: The predictors of outcome. Respir Med 2016; 117: 109-115
  • 18 Rank MA, Hagan JB, Park MA. et al. The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2013; 131 (03) 724-729
  • 19 Martinez FD, Chinchilli VM, Morgan WJ. et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377 (9766): 650-657
  • 20 Mirabelli MC, Beavers SF, Chatterjee AB, Moorman JE. Age at asthma onset and subsequent asthma outcomes among adults with active asthma. Respir Med 2013; 107 (12) 1829-1836
  • 21 Granell R, Henderson AJ, Sterne JA. Associations of wheezing phenotypes with late asthma outcomes in the Avon Longitudinal Study of Parents and Children: a population-based birth cohort. J Allergy Clin Immunol 2016; 138 (04) 1060-1070 .e11
  • 22 Price D, Chisholm A, Hillyer E. et al. Effect of inhaled corticosteroid therapy step down and dosing regimen on measures of asthma control. J Allergy Ther 2013; 4: 1-8
  • 23 Chipps BE, Bacharier LB, Murphy KR. et al. The asthma controller step-down Yardstick. Ann Allergy Asthma Immunol 2019; 122 (03) 241-262 .e4
  • 24 Usmani OS, Kemppinen A, Gardener E. et al. A randomized pragmatic trial of changing to and stepping down fluticasone/formoterol in asthma. J Allergy Clin Immunol Pract 2017; 5 (05) 1378-1387 .e5
  • 25 Songmuang A, Chiyasong S, Waleekhachonloet O. Patterns and Successful in Stopping Budesonide Inhaler Use in Asthmatic Patients Aged 1–5 years: A Retrospective Study [Internet]. SRIMEDJ 2017 [cited 2022 Apr. 9];32(6):571–8. Accessed March 23, 2023 at: